What is the 13F Pro Quality Score for XOMA?

13F Pro ranks XOMA Royalty Corp (XOMA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XOMA's current score at https://13fpro.ai/research/XOMA (free sign-up required for the full ranking).

Which hedge funds own the most XOMA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XOMA include BVF /IL, MORGAN STANLEY, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/XOMA as soon as new 13F filings post.

Where does 13F Pro source XOMA data?

All XOMA Royalty Corp fundamentals and ownership data come directly from SEC EDGAR. XOMA Royalty Corp files with the SEC under CIK 791908. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XOMA in?

XOMA Royalty Corp (XOMA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives XOMA's revenue?

Per XOMA Royalty Corp's latest 10-Q filed with the SEC on 2026-05-12, the biggest revenue drivers are: Income from purchased receivables under EIR method ($9.2M, +52% YoY); Income from purchased receivables under cost recovery method ($2.8M, -50% YoY); Revenue recognized under units-of-revenue method ($0.3M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/XOMA.

What are XOMA's largest expenses?

XOMA Royalty Corp's latest 10-Q reports these as the largest expense items: General and administrative ($11.9M, +46% YoY); Amortization of intangible assets ($0.9M, +64% YoY); Interest expense ($3.4M, -3% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is XOMA research updated on 13F Pro?

XOMA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

XOMA Royalty Corp(XOMA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 791908 XOMA stock profile & AI dashboard →

13F Pro Quality Score

74.0/100

Rank #171 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

96.4/100

Profitability

97.5/100

Balance Sheet

88.4/100

Earnings Quality

30.0/100

Free Cash Flow

96.4/100

Institutional Flow

96.3/100

Revenue Scale

4.2/100

Dilution Risk

10.4/100

XOMA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for XOMA Royalty Corp (XOMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XOMA at 74.0/100 on a 32-signal composite quality model, placing it at rank #171 of 2,879 stocks — the top 10% of the AI-ranked universe. XOMA scores in the top quartile across profitability (97.5), revenue growth (96.4), free cash flow (96.4). Areas of concern include revenue scale (4.2) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), XOMA Royalty Corp reports quarterly revenue of $12.3M, net income of $4.5M, free cash flow of $6.1M. Top institutional holders of XOMA by reported 13-F value include BVF /IL, MORGAN STANLEY, FMR, based on the most recent SEC filings. XOMA trades on the Nasdaq exchange and files with the SEC under CIK 791908. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XOMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XOMA Royalty Corp directly from SEC EDGAR. XOMA Royalty Corp's 13F Pro composite quality score has ranged between 10 and 74 since 2024, currently 74.0 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.

✦

Fun facts about XOMA Royalty Corp

Quirks, history, and lore behind XOMA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap healthcare company listed on Nasdaq, headquartered in Northern California, that holds royalty interests rather than developing drugs itself.
2
The Numbers
Revenue is modest — think tens of millions annually — because the model is purely passive income: collect a cut when others sell, and sit back.
3
The History
The company has roots going back to the 1980s biotech boom and spent decades as a conventional drug developer before pivoting to a pure royalty model in the 2010s.
4
The Secret
It doesn't run labs, hire scientists, or conduct clinical trials — it acquires royalty rights on FDA-approved or late-stage drugs and lets larger pharma companies do all the heavy lifting.
5
The Lore
Think of it as the landlord of biotech: it owns a portfolio of milestone and royalty rights spread across multiple therapeutic areas, clipping coupons every time a partnered drug sells.
6
The Giveaway
Its four-letter ticker doubles as a surname, its business is literally biotech royalties, and it trades on Nasdaq under a name that sounds like a European monarch crossed with a biopharma.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving XOMA's Business? Latest 10-Q Breakdown

✓ 19/19 datapoints verified

AI-extracted from XOMA Royalty Corp's 10-Q filed 2026-05-12 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

XOMA Royalty generated $12.3M in total income and revenues (down 23% YoY) but reported net income of $4.5M, boosted by $3.5M gain on Generation Bio acquisition; company announced agreement to be acquired by Ligand for $39/share.

Biggest Revenue Drivers

Total revenue: $12.3M-23% YoY

Income from purchased receivables under EIR method$9.2M+52% YoY

Includes VABYSMO ($6.7M), MIPLYFFA ($2.3M), and IXINITY ($0.2M); MIPLYFFA reclassified to EIR from cost recovery method in Q4 2025.

Income from purchased receivables under cost recovery method$2.8M-50% YoY

OJEMDA royalties; prior year included $4.0M EMA milestone payment to Day One.

Revenue recognized under units-of-revenue method$0.3M

Amortization of unearned revenue from 2016 HCRP royalty sale arrangements.

Revenue from contracts with customers$0.0Mn/a

No revenue recognized; prior year included $4.0M Takeda milestone payment.

Largest Expense Items

General and administrative$11.9M+46% YoY

Increases in salaries (+$0.9M), lease expense (+$0.6M), tax services (+$0.6M), legal (+$0.5M), and litigation costs (+$0.7M) related to Janssen litigation.

Amortization of intangible assets$0.9M+64% YoY

Includes Pulmokine seralutinib IP ($0.5M) and BioInvent contract-based intangible asset ($0.3M).

Interest expense$3.4M-3% YoY

Accrued interest on Blue Owl Loan ($2.8M), accretion of debt discount/issuance costs ($0.3M), and delayed draw term loan termination expense ($0.3M).

Research and development$0.0M-96% YoY

Prior year included $1.0M pass-through licensing fees and Kinnate clinical trial costs.

Margins: Operating loss of $0.5M despite $12.3M in revenues reflects high G&A expenses of $11.9M and amortization of $0.9M; net income of $4.5M benefited from $3.5M non-recurring gain on Generation Bio acquisition and $4.8M other income (arranger fee, sublease income, CVR adjustments).

Watch Items from the Filing

Three customers represent 54%, 22%, and 19% of Q1 2026 total income and revenues, with Affitech (VABYSMO) alone generating 54% ($6.7M EIR method income plus $11.9M cash receipts).
Ligand acquisition announced April 27, 2026 at $39/share ($739M equity value) plus CVR tied to Janssen litigation outcome; pending stockholder and regulatory approval, expected close Q3 2026.
Blue Owl Loan principal balance $102.8M (net of discount/issuance costs) with $6.4M paid down in Q1 2026; interest payments dependent on VABYSMO royalty receipts; $2.1M in restricted cash held for interest/fee reserve.
Pending litigation against Janssen for breach of contract and unjust enrichment related to TREMFYA commercialization; court denied motion to dismiss in December 2025; litigation is inherently uncertain with no assurance of recovery timing or amount.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$12.3M

Net Income

Q1 2026

$4.5M

Free Cash Flow

Q1 2026

$6.1M

D/E Ratio

Q1 2026

1.11

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-21.1% YoY

$4.8MFY 2023

FY19 $18.4MFY21 $38.2MFY22 $6.0MFY23 $4.8M

Net Income

-138.7% YoY

$-40.8MFY 2023

FY19 $-2.0MFY21 $15.8MFY22 $-17.1MFY23 $-40.8M

Operating Income

-140.3% YoY

$-41.8MFY 2023

FY19 $-3.9MFY21 $17.5MFY22 $-17.4MFY23 $-41.8M

EPS (Diluted)

-104.0% YoY

$-4.04FY 2023

FY19 $-0.23FY21 $0.65FY22 $-1.98FY23 $-4.04

Total Assets

+66.9% YoY

$234.3MFY 2023

FY19 $95.7MFY21 $166.6MFY22 $140.4MFY23 $234.3M

Total Debt

$124.1MFY 2023

FY19 $37.5MFY21 —FY22 $0.00FY23 $124.1M

Op. Cash Flow

-41.0% YoY

$-18.2MFY 2023

FY19 $-285.0KFY21 $22.7MFY22 $-12.9MFY23 $-18.2M

Metric	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018	FY 2017
Revenue	$4.8M -21.1%	$6.0M -84.2%	$38.2M +107.7%	$18.4M +246.7%	$5.3M -89.9%	$52.7M
Net Income	$-40.8M -138.7%	$-17.1M -208.3%	$15.8M +897.1%	$-2.0M +85.1%	$-13.3M -191.4%	$14.6M
Operating Income	$-41.8M -140.3%	$-17.4M -199.3%	$17.5M +551.2%	$-3.9M +77.0%	$-16.9M -199.0%	$17.0M
EPS (Diluted)	$-4.04 -104.0%	$-1.98 -404.6%	$0.65 +382.6%	$-0.23 +85.5%	$-1.59 -317.8%	$0.73
Total Assets	$234.3M +66.9%	$140.4M -15.7%	$166.6M +74.0%	$95.7M +50.1%	$63.8M +41.9%	$44.9M
Total Debt	$124.1M	$0.00	—	$37.5M +66.6%	$22.5M +54.3%	$14.6M
Operating Cash Flow	$-18.2M -41.0%	$-12.9M -156.8%	$22.7M +8057.2%	$-285.0K +97.7%	$-12.6M -570.7%	$2.7M

AI Insight: XOMA Financial Trends

Debt has declined $18M over eight quarters while equity recovers, but operating income remains near breakeven and highly volatile.

• Total debt fell steadily from $121M in Q2 2024 to $103M in Q1 2026, a reduction of $18M over eight quarters.

• Operating income has been erratic, swinging from -$16M in Q3 2024 to $6M in Q1 2025 and back near zero (-$0M) in Q1 2026.

• Equity recovered from a trough of $72M in Q2 2025 to $93M in Q1 2026, the highest level in the observed period.

• Operating cash flow turned positive at $6M in Q1 2026 after three consecutive negative or near-zero quarters.

⚠ Operating income has not exceeded $6M in any quarter; sustained profitability at the operating level remains unproven.

⚠ Net income diverges sharply from operating income each quarter, signaling heavy reliance on non-operating items — a volatile earnings driver.

⚠ Revenue ranged from $7M to $16M with no clear upward trend; top-line predictability is a key risk for a royalty model.

AI Insight: XOMA Ratio Trends

XOMA's profitability is highly erratic quarter-to-quarter, but D/E has edged down to 1.11 — its lowest in the dataset — offering a modest balance-sheet positive amid volatile margins.

• Operating margin swings wildly: from -83.2% in Q4 2024 to 37.3% in Q1 2025, then back to -3.9% in Q1 2026, signaling lumpy royalty income.

• Net profit margin stays persistently positive (36.2% in Q1 2026) even when operating margin turns negative, suggesting significant non-operating income.

• D/E declined from a peak of 1.57 in Q2 2025 to 1.11 in Q1 2026 — the lowest level recorded in this dataset.

• ROIC turned negative again at -1.0% in Q1 2026, down from 4.5% in Q4 2025, reflecting inconsistent core capital deployment.

⚠ ROIC has now been negative in four of the eight quarters shown — sustained capital inefficiency risk for long-term holders.

⚠ The wide gap between NPM (36.2%) and OpMargin (-3.9%) in Q1 2026 warrants scrutiny; royalty/milestone timing drives unpredictable earnings.

⚠ ROE fell sharply from 63.9% in Q2 2025 to 19.2% in Q1 2026 — monitor whether equity returns can stabilize at a meaningful level.

Get alerted when XOMA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for XOMA Royalty Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XOMA

BVF INC/IL
$81.3M2,590,303 sh
MORGAN STANLEY
$53.4M1,702,157 sh
FMR LLC
$40.9M1,302,974 sh
BlackRock, Inc.
$20.3M646,914 sh
Woodline Partners LP
$20.1M640,001 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.2M549,796 sh
Opaleye Management Inc.
$9.4M300,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$7.2M229,766 sh
MILLENNIUM MANAGEMENT LLC
$6.4M204,920 sh
STATE STREET CORP
$6.1M193,148 sh

Fund	Value	Shares
BVF INC/IL	$81.3M	2,590,303
MORGAN STANLEY	$53.4M	1,702,157
FMR LLC	$40.9M	1,302,974
BlackRock, Inc.	$20.3M	646,914
Woodline Partners LP	$20.1M	640,001
VANGUARD CAPITAL MANAGEMENT LLC	$17.2M	549,796
Opaleye Management Inc.	$9.4M	300,000
GEODE CAPITAL MANAGEMENT, LLC	$7.2M	229,766
MILLENNIUM MANAGEMENT LLC	$6.4M	204,920
STATE STREET CORP	$6.1M	193,148

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XOMA on your watchlist

Track score changes the day XOMA Royalty Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XOMA a good stock to buy?

13F Pro's AI-powered analysis of XOMA Royalty Corp (XOMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XOMA are available on the XOMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XOMA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XOMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of XOMA Royalty Corp's investment landscape.